Sun Pharma Advanced Research Share Price
Sun Pharma Advanced Research Share Price Today
As of 20 Jul 2026, Sun Pharma Advanced Research share price is ₹227.51. The stock opened at ₹234.89, compared to its previous close of ₹235.20. During today's trading session, Sun Pharma Advanced Research share price moved in the range of ₹226.66 to ₹238.39, with an average price of ₹232.52 for the day. Looking at its last 52-week, the stock has touched a low of ₹108.00 and a high of ₹289.00. On the performance front, Sun Pharma Advanced Research share price has increased by 76.15% over the last six months and is up 45.71% on a year-on-year basis.
Sun Pharma Advanced Research Returns Calculator
Sun Pharma Advanced Research Shareholder Returns
Sun Pharma Advanced Research Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,63,815.00 | 36.73 | 5.05 | 14.85% | 0.55 | 18.72% | 18.85 | 0.91% | 0.56 | 10.90 |
| Divis Laboratories | 1,92,678.00 | 61.36 | 9.40 | 16.19% | 0.00 | 21.00% | 9.43 | 0.50% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,61,323.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,14,585.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Zydus Lifesciences | 1,13,990.00 | 17.39 | 3.23 | 19.69% | 0.35 | 20.30% | 3.70 | 0.11% | 0.39 | 35.38 |
| Lupin | 1,11,661.00 | 19.83 | 4.71 | 27.01% | 0.03 | 27.44% | 3.51 | 0.78% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,896.00 | 1.05 | 0.12 | 12.65% | 0.42 | 12.97% | 5.05 | 0.05% | 0.54 | 49.37 |
| Dr. Reddy's Laboratories | 1,01,067.00 | 24.97 | 2.75 | 11.64% | 0.15 | 13.65% | 3.32 | 0.64% | 0.63 | 38.68 |
| Aurobindo Pharma | 89,097.90 | 25.44 | 2.35 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,639.30 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
Sun Pharma Advanced Research Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Revenue | ₹71.77 | ₹75.55 | ₹238.78 |
| Other Income | ₹1.79 | ₹29.47 | ₹10.88 |
| Total Revenue | ₹73.56 | ₹105.01 | ₹249.66 |
| Total Expenses | ₹416.34 | ₹491.85 | ₹472.24 |
| Profit Before Tax | -₹342.78 | -₹386.83 | -₹222.58 |
| Tax | -₹0.27 | ₹0.38 | ₹0.00 |
| Profit After Tax | -₹342.51 | -₹387.21 | -₹222.58 |
| EPS - Basic | -₹10.55 | -₹11.93 | -₹7.82 |
| EPS - Diluted | -₹10.55 | -₹11.93 | -₹7.82 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Profit before tax | -₹342.78 | -₹386.83 | -₹222.58 |
| Income before WC changes | -₹322.26 | -₹397.74 | -₹215.59 |
| Change in Assets | ₹2.92 | -₹47.88 | ₹5.40 |
| Change in Liabilities | -₹49.78 | ₹20.54 | ₹135.71 |
| Change in WC | -₹46.86 | -₹27.33 | ₹141.11 |
| Cash flow from Operations | -₹360.29 | -₹429.19 | -₹69.12 |
| Cash flow from Investing | ₹157.66 | ₹391.53 | -₹548.28 |
| Cash flow from Financing | ₹199.26 | ₹42.41 | ₹616.76 |
| Total Cash Flow | -₹3.38 | ₹4.74 | -₹0.64 |
| Cash (Start of the year) | ₹5.33 | ₹0.58 | ₹1.22 |
| Cash (End of the year) | ₹1.96 | ₹5.33 | ₹0.58 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Non-Current Assets | ₹309.34 | ₹245.66 | ₹375.16 |
| Current Assets | ₹26.20 | ₹269.39 | ₹454.96 |
| Total Assets | ₹335.53 | ₹515.04 | ₹830.13 |
| Current Liabilities | ₹374.24 | ₹265.06 | ₹178.95 |
| Net Current Asset | -₹348.04 | ₹4.33 | ₹276.02 |
| Non-Current Liabilities | ₹178.24 | ₹124.23 | ₹138.41 |
| Equity Capital | -₹216.95 | ₹125.76 | ₹512.78 |
| Total Equity & Liabilities | ₹335.53 | ₹515.04 | ₹830.13 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹71.77 | ₹75.55 | ₹238.78 | ₹137.25 |
| Other Income | ₹1.79 | ₹29.47 | ₹10.88 | ₹6.84 |
| Total Revenue | ₹73.56 | ₹105.01 | ₹249.66 | ₹144.09 |
| Total Expenses | ₹418.78 | ₹493.12 | ₹472.24 | ₹347.49 |
| Profit Before Tax | -₹345.22 | -₹388.11 | -₹222.58 | -₹203.40 |
| Tax | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Profit After Tax | -₹345.22 | -₹388.11 | -₹222.58 | -₹203.40 |
| EPS - Basic | -₹10.64 | -₹11.96 | -₹7.82 | -₹7.73 |
| EPS - Diluted | -₹10.64 | -₹11.96 | -₹7.82 | -₹7.73 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹345.22 | -₹388.11 | -₹222.58 | -₹203.40 |
| Income before WC changes | -₹326.40 | -₹399.44 | -₹215.59 | -₹186.72 |
| Change in Assets | -₹19.94 | -₹25.34 | ₹5.40 | -₹36.53 |
| Change in Liabilities | -₹26.86 | -₹0.54 | ₹135.71 | ₹10.47 |
| Change in WC | -₹46.80 | -₹25.88 | ₹141.11 | -₹26.05 |
| Cash flow from Operations | -₹362.41 | -₹429.43 | -₹69.12 | -₹208.23 |
| Cash flow from Investing | ₹157.66 | ₹391.11 | -₹548.28 | -₹29.17 |
| Cash flow from Financing | ₹200.88 | ₹42.80 | ₹616.76 | ₹229.32 |
| Total Cash Flow | -₹3.87 | ₹4.48 | -₹0.64 | -₹8.08 |
| Cash (Start of the year) | ₹5.06 | ₹0.58 | ₹1.22 | ₹9.30 |
| Cash (End of the year) | ₹1.19 | ₹5.06 | ₹0.58 | ₹1.22 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹304.02 | ₹239.93 | ₹375.16 | ₹208.93 |
| Current Assets | ₹25.26 | ₹246.41 | ₹454.96 | ₹71.15 |
| Total Assets | ₹329.28 | ₹486.33 | ₹830.13 | ₹280.08 |
| Current Liabilities | ₹373.72 | ₹243.89 | ₹178.95 | ₹171.43 |
| Net Current Asset | -₹348.46 | ₹2.52 | ₹276.02 | -₹100.28 |
| Non-Current Liabilities | ₹176.17 | ₹117.59 | ₹138.41 | ₹77.43 |
| Equity Capital | -₹220.62 | ₹124.86 | ₹512.78 | ₹31.23 |
| Total Equity & Liabilities | ₹329.28 | ₹486.33 | ₹830.13 | ₹280.08 |
About Sun Pharma Advanced Research
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company’s therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. The Company’s other programs include Sezaby for the treatment of neonatal seizures, Vodobatinib for the treatment of neurodegenerative disorders (SCC-138), Vibozilimod for the treatment of autoimmune disorders (SCD-044), SCD-153 for the treatment of alopecia areata, SBO-154 for multiple cancer indications and SCO-155 for treatment of cancer. SBO-154 is an anti MUC1 ADC being developed for multiple tumor types expressing MUC1.
Sun Pharma Advanced Research Financial Highlights
- Revenue: Sun Pharma Advanced Research reported revenue of ₹1,890.12 crore in FY26 vs ₹73.56 crore in FY25. It showed an increase of 2,469.49% on a yearly basis.
- Operating Profit: Sun Pharma Advanced Research reported an operating profit of ₹1,553.01 crore in FY26 vs ₹342.78 crore in FY25. It showed an increase of 553.06% on a year-on-year basis.
- Net Profit: Sun Pharma Advanced Research reported a net profit of ₹1,553.20 crore in FY26 vs ₹342.51 crore in FY25. It showed an increase of 553.48% on a yearly basis.
Sun Pharma Advanced Research Quarterly Result Highlights
- Sun Pharma Advanced Research reported revenue of ₹1,855.02 crore in Mar 2026, compared with ₹8.45 crore in Dec 2025, representing an increase of 21,852.90% on a quarter-on-quarter (QoQ) basis.
- Sun Pharma Advanced Research reported an operating profit of ₹1,760.96 crore in Mar 2026, compared with ₹80.35 crore in Dec 2025, representing an increase of 2,291.61% on a quarter-on-quarter (QoQ) basis.
- Sun Pharma Advanced Research reported a profit of ₹1,761.34 crore in Mar 2026, compared with ₹80.42 crore in Dec 2025, reflecting an increase of 2,290.18% on a QoQ basis.
- The earnings per share (EPS) of Sun Pharma Advanced Research stood at ₹10.55 during Mar 2026.
Similar Stocks
FAQs on Sun Pharma Advanced Research Share Price
What is Sun Pharma Advanced Research share price today?
Sun Pharma Advanced Research share price is ₹227.51 as on 20 Jul, 2026, 15:57 IST.
How has the Sun Pharma Advanced Research share price performed in the past?
In the last 1 year, Sun Pharma Advanced Research delivered a return of 45.71%. The Sun Pharma Advanced Research share price hit a high of ₹289.00 and low of ₹108.00.
How much is the Mutual Fund shareholding in Sun Pharma Advanced Research shares?
The Mutual Fund Shareholding in Sun Pharma Advanced Research was 0.09% at the end of May 2026.
What is the the 52-week high and low of Sun Pharma Advanced Research shares ?
The 52-week high and low of Sun Pharma Advanced Research share is ₹289.00 and ₹108.00 as of 20 Jul, 2026.
What is the market cap of Sun Pharma Advanced Research?
The market capitalisation of Sun Pharma Advanced Research is ₹7,634.37 Crores as on 20 Jul, 2026.
What are the stock symbols of Sun Pharma Advanced Research?
The stock symbol of Sun Pharma Advanced Research is SPARC on the NSE, 532872 on the BSE, and the ISIN is INE232I01014.
What was yesterday's closing price of Sun Pharma Advanced Research shares ?
Sun Pharma Advanced Research shares closed yesterday at ₹235.20 on NSE & ₹235.25 on BSE
How to buy Sun Pharma Advanced Research shares?
To buy Sun Pharma Advanced Research shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Sun Pharma Advanced Research shares on Holidays?
No, shares of Sun Pharma Advanced Research or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Sun Pharma Advanced Research shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Sun Pharma Advanced Research?
The PE and PB ratio of Sun Pharma Advanced Research is 4.92 and 5.7 respectively, as on 20 Jul, 2026, 15:57 IST.